SEC Form 4 · accession 0001209191-16-128709
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael E Lewis
Officer — Chief Scientific Advisor
Period of report
May 4, 2016
Accepted (ET)
Jun 17, 2016 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.81 | May 4, 2016 | A | 20,000 | A | — | May 4, 2026 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on June 4, 2016, in each case subject to the reporting person's Continuous Service (as defined in the 2014 Equity Incentive Plan) as of each such date.